AMERICAN JOURNAL OF HEMATOLOGY: Eosinophilic disease as defined by the World Health Organization: Diagnosis, risk stratification and management update in 2021.

Eosinophilia includes a wide range of non-hematological (secondary or reactive) and hematological (primary or clonal) diseases, and may lead to end-organ damage
.

An article published in AMERICAN JOURNAL OF HEMATOLOGY recently updated the diagnosis, risk stratification and management of eosinophilic diseases

Diagnosis :

Diagnosis : Diagnosis :Diagnosis:Diagnosis

Hypereosinophilia is usually defined as a peripheral blood eosinophil count greater than 1.
5×10 9 /L, which may be related to tissue damage
.

After excluding secondary causes of eosinophilia, the diagnostic evaluation of primary eosinophilia relies on a combination of various tests, including morphological review of blood and bone marrow, standard cytogenetics, Fluorescence in situ hybridization and flow immunophenotyping to detect histopathological or clonal evidence of non-acute or chronic hemolymphoid tumors

immunity

Risk stratification:

Risk stratification: Risk stratification: Risk stratification:

The prognosis of the disease depends on identifying the subtype of eosinophilia
.

After evaluating the secondary causes of eosinophilia, the World Health Organization approved a semi-molecular classification scheme for disease subtypes in 2016

Risk adaptation treatment:

Risk adaptation treatment: Risk adaptation treatment:

The purpose of treatment is to reduce organ damage mediated by eosinophils
.

Patients with mild eosinophilia (such as <1.

Manage stem cells

 

Original source:

Shomali, W.

Shomali, W.
and Gotlib, J.
(2021), World Health Organization-defined eosinophilic disorders: 2021 update on diagnosis, risk stratification, and management.
Am J Hematol.
Accepted Author Manuscript.
https://doi.
org/10.
1002/ ajh.
26352 Leave a message here